Bristol-Myers Squibb: News
Partnering News
April 1, 2016Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.March 23, 2016Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.February 16, 2016Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramFebruary 1, 2016Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in JapanDecember 18, 2015Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV HealthcareDecember 14, 2015Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramDecember 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.December 8, 2015Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton UniversityDecember 4, 2015Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation’s 2015 Collaborator AwardNovember 2, 2015Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.October 15, 2015Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody ProgramSeptember 25, 2015Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy ProgramAugust 31, 2015Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic DiseasesAugust 30, 2015Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology AntibodiesJuly 29, 2015Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.July 15, 2015MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic DiseasesApril 16, 2015Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North AmericaApril 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.April 6, 2015Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular DiseasesMarch 24, 2015Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 4, 2015Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer ImmunotherapyFebruary 23, 2015Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.February 23, 2015Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related IndicationsJanuary 29, 2015Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo® in Advanced Refractory Solid TumorsJanuary 13, 2015Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galunisertib in Advanced Solid Tumors

You are leaving to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.